Edition:
United States

Aradigm Corp (ARDM.OQ)

ARDM.OQ on NASDAQ Stock Exchange Capital Market

1.36USD
14 Aug 2018
Change (% chg)

$-0.01 (-0.73%)
Prev Close
$1.37
Open
$1.36
Day's High
$1.36
Day's Low
$1.36
Volume
100
Avg. Vol
10,870
52-wk High
$7.26
52-wk Low
$1.04

Chart for

About

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery... (more)

Overall

Beta: 8.64
Market Cap(Mil.): $21.07
Shares Outstanding(Mil.): 15.21
Dividend: --
Yield (%): --

Financials

  ARDM.OQ Industry Sector
P/E (TTM): -- 169.61 31.56
EPS (TTM): -0.79 -- --
ROI: -430.54 1.42 12.88
ROE: -- 0.52 15.04

BRIEF-Aradigm Q1 Loss Per Share $0.32

* Q1 REVENUE $1.5 MILLION VERSUS $1.7 MILLION Source text for Eikon: Further company coverage:

May 15 2018

BRIEF-Aradigm Announces EMA Has Completed Its Validation Of The MAA Submission

* ARADIGM ANNOUNCES THE EMA HAS COMPLETED ITS VALIDATION OF THE MAA SUBMISSION

Apr 05 2018

BRIEF-Aradigm Reports Q4 Loss Per Share Of $0.28

* ARADIGM ANNOUNCES FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS

Mar 23 2018

BRIEF-Aradigm Submits Marketing Authorisation Application To EMA For EU Marketing Approval Of Linhaliq

* ARADIGM SUBMITS MARKETING AUTHORISATION APPLICATION (MAA) TO EMA FOR EU MARKETING APPROVAL OF LINHALIQ IN NON-CYSTIC FIBROSIS BRONCHIECTASIS Source text for Eikon: Further company coverage:

Mar 09 2018

Earnings vs. Estimates